GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Can Stem Cell Infusions Cause Fever?

Yes. Stem cell infusions can cause fever, but fever after treatment should not automatically be dismissed as a harmless reaction. A 2024 meta-analysis of 152 randomized trials reported an association between mesenchymal stromal cell (MSC) therapy and fever: odds ratio 1.61, with a 95% confidence interval of 1.22–2.11. That is a comparison with control groups, not a 61% chance of developing fever. 011574888X179799231023060734

Transient fever has been reported within about 48 hours of MSC administration, but timing alone cannot distinguish an infusion reaction from infection. The evidence also covers different cell products, diseases, and delivery routes; it cannot give one reliable fever percentage for every infusion. S13287 021 02609 x

Can Stem Cell Infusions Cause Fever?

If you have a fever now, contact your treating team promptly. During cancer treatment, a temperature around 38°C (100.4°F) or higher warrants an immediate call. Do not take fever medicine before asking the team, because it can hide a serious problem. If you have breathing difficulty, confusion, or fainting, seek emergency care rather than waiting for a clinic reply. Infection

When does fever need urgent care?

After a blood stem cell transplant or CAR-T treatment, or if you have been told your neutrophils are low, follow your treatment team’s emergency plan. Fever may be the first sign of infection during neutropenia. Do not wait to see whether it goes away overnight.

Low neutrophils and fever thresholds

For adults with cancer, commonly used clinical fever criteria are a single oral temperature of at least 38.3°C (101°F), or 38.0°C (100.4°F) sustained for one hour. Severe neutropenia means an absolute neutrophil count below 500 cells/µL, or expected to fall below that level. These are clinical assessment criteria—not instructions to delay calling until an hour has passed. Follow any earlier call threshold your team gave you. Neutropenic%20fever%20Guideline%20Updated%206 7 23.pdf

Febrile neutropenia requires urgent assessment. ASCO/IDSA guidance for adults with cancer recommends initial empirical antibiotics within one hour of triage, before the organism causing a possible infection is necessarily known. This is a clinician-managed emergency, not a reason to take leftover antibiotics at home. Fever and neutropenia in adults with cancer

Symptoms that should not wait

  • Seek emergency care now for difficulty breathing, swelling of the face or tongue, fainting, confusion, or a seizure.
  • Get urgent medical assessment for shaking chills, a severe headache or stiff neck, very little urine, or repeated vomiting that prevents you from keeping fluids down.
  • Call the treating team immediately for fever after transplant or CAR-T therapy, during known neutropenia, or at the threshold in your written discharge instructions.

If fever persists or returns after settling, contact the team again; a previous reassuring assessment does not explain a new episode. A reading below 38°C does not override serious symptoms or an individualized emergency plan.

Which kind of treatment did you receive?

MSC means mesenchymal stromal cell, often marketed as a mesenchymal stem cell. These are different from the blood-forming cells used in a hematopoietic stem cell transplant (HSCT). CAR-T uses modified immune cells, not stem cells. Identifying the product and route matters more than the broad phrase “stem cell therapy.”

  • MSC therapy: cells may be delivered into a vein or by a local injection. Research results from one route should not be applied to another.
  • Blood stem cell transplant: fever is assessed in the context of conditioning treatment, immune suppression, infection risk, and blood-cell recovery.
  • Private clinic treatment: ask for the cell source, product name, dose, route, and regulatory status. A clinic service is not interchangeable with an approved product or a controlled trial.

A regenerative medicine overview can help you identify the terms on a treatment proposal, but the treating clinician should confirm exactly what you will receive.

Why can an infusion cause fever?

Infusion or allergic reactions

Fever during or soon after an infusion can accompany a reaction to the product or its ingredients. The US prescribing information for Ryoncil, an intravenous donor bone marrow MSC product, warns about hypersensitivity and acute infusion reactions, including fever, difficulty breathing, and low blood pressure. It recommends corticosteroid and antihistamine premedication. Those instructions are product-specific; they are not a home-treatment plan for every infusion. Tell the supervising staff immediately if symptoms start while the drip is running. DrugInfo.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659

Inflammatory responses

A temporary inflammatory response is one possible explanation for post-MSC fever. However, the repeated fever signal in trials does not establish the cause of an individual patient’s fever, and feeling otherwise well does not rule out infection. S13287 021 02609 x

Infection

Fever can also reflect infection. The Ryoncil label warns that transmission of infectious agents remains possible despite donor screening and manufacturing controls. Separately, cancer treatment can lower infection-fighting white cells. These are different risks, and neither can be excluded with a thermometer alone. DrugInfo.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659 Infection

How common is fever after MSC treatment?

There is no single percentage that applies to every MSC infusion. The studies below differ in disease, cell source, delivery route, and adverse-event reporting. Their populations may also overlap, so their sample sizes should not be added together.

Evidence Study population and scope Fever finding Important limit
2024 MSC meta-analysis 152 randomized trials; the abstract reports 9,228 MSC-treated individuals across several cell sources. Odds ratio 1.61 (95% CI 1.22–2.11) versus controls. 011574888X179799231023060734 A pooled association, not a universal fever rate or an IV-only estimate.
2021 MSC meta-analysis 62 randomized trials, 3,546 participants; intravenous or local administration across about 20 disease categories. Transient-fever odds ratio 3.65 (95% CI 2.05–6.49). S13287 021 02609 x Not every trial reported fever; the result does not predict an individual’s risk.
2026 umbilical cord MSC review 42 randomized trials, 2,280 adults receiving intravascular treatment; 15 trials with 954 participants reported fever within 24 hours. In that fever-reporting subset, relative risk 2.34 (95% CI 1.02–5.35). Szag029 The fever estimate comes from 15 trials, not all 42; it applies to cord-derived MSCs.
Ryoncil US prescribing information 54 children treated for steroid-refractory acute graft-versus-host disease after transplant. Fever in 19/54 (35%); grade 3 fever in 2/54 (4%); serious pyrexia in 5/54 (9%). DrugInfo.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659 A single-arm, severely ill pediatric population—not a wellness-infusion risk estimate.

Odds ratio and relative risk are not the same measure. Neither provides your absolute chance of fever without the underlying event rates. The different estimates above should not be read as a ranking of which product is safer.

Can your own cells cause fever?

Yes. The 2012 SafeCell review found increased fever in four small randomized trials using autologous MSCs—cells from the recipient’s own body. The pooled odds ratio was 16.82, but its very wide 95% confidence interval, 5.33–53.10, makes it an imprecise historical estimate. “Your own cells” does not mean “no fever risk.” Journal.pone.0047559

When can fever start, and how long can it last?

The first day is a documented window in MSC research: the 2026 cord-MSC review measured fever within 24 hours, while the 2021 review described transient fever occurring within about 48 hours. When fever begins is not the same as how long it lasts. These findings do not justify promising that every post-infusion fever will resolve within 24–48 hours. Szag029 S13287 021 02609 x

Fever can occur after a later dose even if the first infusion caused none. In a Chinese phase 2 study of intravenous umbilical cord MSCs for type 2 diabetes, 4 of 24 recipients developed transient fever within 24 hours, after their second or third infusion; none of 10 saline controls did. Participants were followed for 24 weeks. This small, disease-specific study does not establish a general incidence rate. Wjcc.v11.i21.5083

Do not wait for a study’s reported fever window to end before seeking advice. Infection and treatment-related inflammation cannot be assigned to separate, reliable time slots.

Why transplant, injection, and CAR-T fevers differ

After a blood stem cell transplant

Infection is a priority to exclude, but fever can also accompany engraftment syndrome while neutrophils recover. This syndrome may include rash, diarrhea, lung inflammation or fluid accumulation, and liver or kidney problems. Its assessment and treatment require the transplant team; a suspected inflammatory cause does not remove the need to investigate infection. PMC9718873

After a joint injection

A hot, swollen, painful joint with fever needs urgent assessment for septic arthritis. Sudden severe joint pain or difficulty moving the joint also warrants urgent help, even without a high temperature. Do not assume this is an expected response to injected cells. Septic arthritis

After delivery into brain fluid

A South Korean phase 1 study gave repeated intracerebroventricular injections of umbilical cord blood MSCs to nine people with Alzheimer’s disease. All nine developed fever within 6–24 hours; the fever subsided within the following 36 hours. Three serious drug reactions in two participants prolonged hospitalization. This was delivery into the brain’s ventricular fluid space—not an intravenous infusion—and its results cannot be used as an IV fever rate. Fever with severe headache, neck stiffness, or neurological symptoms needs urgent assessment. S13195 021 00897 2

After CAR-T therapy

CAR-T is not stem cell therapy. It can cause cytokine release syndrome (CRS), with fever, fast heartbeat, low blood pressure, or trouble breathing. CRS can be life-threatening. T cell transfer therapy ASCO guidance describes onset most often at 2–7 days, with delays up to three weeks reported. Follow the CAR-T team’s emergency instructions rather than advice intended for MSC infusions. JCO.21.01992

What to do if you develop a fever

  1. Record the reading and time. Note how you measured it, when treatment occurred, and whether you have already taken any medicine.
  2. Contact the treating team. Give the product name, route, dose date, and symptoms. Mention transplant, CAR-T treatment, immune-suppressing medicines, or known low neutrophils.
  3. Ask before taking fever reducers. Aspirin, acetaminophen, and ibuprofen can conceal a serious problem during cancer treatment. Follow your clinician’s instructions. Infection
  4. Use emergency care for severe symptoms. Do not wait for an email response or travel back to the original clinic if urgent local care is available.

Evaluation depends on the treatment, symptoms, and examination. For suspected neutropenic fever, clinicians obtain blood counts and cultures and investigate possible infection sites. Tests or imaging are selected for the situation; not every person needs the same panel. In suspected febrile neutropenia, treatment should not wait for final culture results. Neutropenic%20fever%20Guideline%20Updated%206 7 23.pdf Fever and neutropenia in adults with cancer

Prepare for an after-hours fever call

Before treatment, ask the team to write down your personal call threshold, the monitoring plan, a clinician’s after-hours number, and where to go if the clinic cannot assess you. Save the product details and discharge instructions somewhere a family member can find them.

If a temperature rise happens at home, this fill-in call note can help you report it clearly:

“I received [product name] by [route] on [date and time]. My temperature is [reading and unit], measured [method] at [time]. My other symptoms are [symptoms]. I have taken [medicine, dose, and time, or none]. My team has told me [whether I have low neutrophils or a transplant/CAR-T emergency plan]. Where should I be assessed now?”

This is a reporting template, not a diagnostic checklist. If you are short of breath, confused, or faint, seek emergency help first. If you are traveling, include a local emergency route and records for your home doctor in your medical travel plan; do not treat a flight booking as the end of follow-up.

What approval means for treatment in Japan

An approved cell product and a clinic’s regenerative medicine provision plan are different things. Japan’s Temcell HS is a donor bone marrow MSC product approved for acute graft-versus-host disease after HSCT. The PMDA review reported fever in 7 of 14 patients in one small study, with 6 cases judged treatment-related. Those figures concern that product and population, not every MSC service offered in Japan. 000215658.pdf

For clinic services, ask whether the intervention is being provided under Japan’s regenerative medicine safety framework, and request the applicable plan details. The distinction between product approval and plan filing matters: submitting a provision plan under the Act on the Safety of Regenerative Medicine is not the same as obtaining marketing approval for a product or proving efficacy. En MHLW publishes notified provision plans, but a registry entry is not an efficacy finding. Published_plan

Regardless of the regulatory route, request a written fever response plan: who assesses you after hours, which hospital can receive you, how records are transferred, and which emergency costs are outside the quoted treatment fee. A registration number cannot answer those questions.

Does fever mean the cells are working?

No. The safety reviews cited here evaluate fever as an adverse event; they do not validate it as a marker of benefit. Fever is not evidence that cells are repairing tissue, and its absence does not establish treatment failure. Ask for disease-specific evidence of benefit rather than accepting fever as proof of success. 011574888X179799231023060734 S13287 021 02609 x

Planning treatment in Japan? Ask how fever is monitored after your infusion, who answers after hours, and where you would go if admission is needed.

You can send your questions to the clinic team before you decide.

Contact the clinic team

The bottom line

Fever is a documented risk of MSC treatment, but there is no single rate for all stem cell infusions. In the 2026 cord-MSC review, the roughly 2.3-fold relative risk came from 15 fever-reporting trials with 954 participants—not all 42 trials in the review. Szag029 Report fever to your treating team, use your individualized emergency plan, and do not assume an early or mild fever is harmless.

This article provides general information from clinical research, regulatory labeling, and public health guidance. It is not an individual diagnosis or a substitute for your treating team’s instructions.